Dupixent's Ranking Among Top-Selling Drugs Worldwide in 2024 | Categorical | | | 7 months ago | |
FDA Approval of Dupixent for COPD by September 27, 2024? | Binary | | | 7 months ago | |
Will Dupixent sales grow in Q4 2024? | Binary | | | 7 months ago | |
Will Dupixent receive additional approvals for new indications by end of 2024? | Binary | | | 7 months ago | |
Market Share of Dupixent in COPD Treatments in Europe by end of 2024 | Categorical | | | 7 months ago | |
Sanofi Stock Price Change Within One Week After FDA Decision on Dupixent | Categorical | | | 7 months ago | |
Most prescribed diabetes drug in Europe by end of 2025? | Categorical | | | 9 days ago | |
Will Eisai and Biogen reapply for Leqembi approval in the EU by December 31, 2024? | Binary | | | 5 months ago | |
Will Kezar Life Sciences receive a clinical hold letter from the FDA by the end of 2024? | Binary | | | 3 months ago | |
How will Kezar Life Sciences' stock price change by December 31, 2024? | Categorical | | | 3 months ago | |
Will Kezar Life Sciences resume enrollment in the Zetomipzomib Lupus Nephritis trial by March 31, 2025? | Binary | | | 3 months ago | |
Will Biogen's stock price recover to its pre-rejection level by December 31, 2024? | Binary | | | 5 months ago | |
What will be the total US sales of Leqembi by December 31, 2024? | Categorical | | | 5 months ago | |
Outcome of vision loss study related to Ozempic by end of 2025? | Categorical | | | 9 days ago | |
Increase in Ozempic prescriptions in Europe post-EMA label update by June 2025? | Binary | | | 9 days ago | |
Mounjaro surpasses Ozempic in European diabetes treatment market share by end of 2025? | Binary | | | 9 days ago | |
Novo Nordisk issues safety update or recall for Ozempic over vision loss by end of 2025? | Binary | | | 9 days ago | |
Primary reason for Ozempic prescription increase in Europe post-EMA update by June 2025? | Categorical | | | 9 days ago | |
Will Kezar Life Sciences announce new safety measures for the Zetomipzomib Lupus Nephritis trial by December 31, 2024? | Binary | | | 3 months ago | |
What will be the outcome of the FDA review of Kezar Life Sciences' Zetomipzomib Lupus Nephritis trial by March 31, 2025? | Categorical | | | 3 months ago | |
What regulatory action will EMA take on Kezar Life Sciences' Zetomipzomib Lupus Nephritis trial by March 31, 2025? | Categorical | | | 3 months ago | |
Will Leqembi be approved in another major market outside the US and EU by December 31, 2024? | Binary | | | 5 months ago | |
How will Biogen's stock price compare to its competitors by December 31, 2024? | Categorical | | | 5 months ago | |
What will be the next major regulatory decision on Leqembi by December 31, 2024? | Categorical | | | 5 months ago | |
